US Cardiac Biomarkers Market Growing Geriatric Population to Boost Growth 2035

US Cardiac Biomarkers Market: Comprehensive Analysis and Future Outlook

The U.S. cardiac biomarkers market is experiencing robust growth, driven by the increasing prevalence of cardiovascular diseases (CVDs), advancements in diagnostic technologies, and a growing emphasis on early disease detection. US Cardiac Biomarkers Market Industry is expected to grow from 3.6(USD Billion) in 2024 to 12.5 (USD Billion) by 2035. The US Cardiac Biomarkers Market CAGR (growth rate) is expected to be around 11.981% during the forecast period (2025 - 2035).

Cardiac biomarkers are substances released into the bloodstream when the heart is damaged or stressed. They play a crucial role in diagnosing and managing various heart conditions, including myocardial infarction, heart failure, and acute coronary syndrome. The increasing demand for these biomarkers is attributed to their ability to provide rapid and accurate diagnostic information, essential for timely treatment.

Request To Free Sample of This Strategic Report - https://www.marketresearchfuture.com/sample_request/12821

Key Market Segments

1. By Type:

• Troponin: Troponin is the most widely used cardiac biomarker due to its high specificity and sensitivity in detecting myocardial infarction. In 2024, the troponin segment held the largest revenue share and is expected to witness the fastest growth during the forecast period. 

• B-type Natriuretic Peptide (BNP) and N-terminal proBNP (NT-proBNP): These biomarkers are primarily used in diagnosing and managing heart failure. The BNP and NT-proBNP segment is expected to grow significantly due to its usage in detecting heart damage and stress.

• Creatine Kinase-MB (CK-MB): CK-MB is used to detect myocardial infarction but has been largely supplanted by troponin due to the latter's higher specificity.

• Myoglobin: Myoglobin is an early marker for muscle injury, including heart muscle, but is less specific than troponin.

2. By Application:

• Acute Coronary Syndrome (ACS): ACS is the leading application segment, accounting for the largest market share due to the high incidence of heart attacks and the necessity for rapid diagnosis.

• Myocardial Infarction: The use of cardiac biomarkers is crucial in diagnosing myocardial infarction, enabling timely intervention.

• Congestive Heart Failure: Biomarkers like BNP and NT-proBNP are essential in diagnosing and managing heart failure.

• Atherosclerosis: Cardiac markers have become valuable tools in atherosclerosis diagnosis, enabling the assessment of novel therapeutic approaches and monitoring treatment efficacy.

3. By Location of Testing:

• Laboratory Testing: Laboratory testing remains the dominant end-use segment, accounting for a significant market share in 2024. Hospital laboratories play a crucial role in modern healthcare by providing in-vitro diagnostic services and supporting clinical decision-making.

• Point-of-Care Testing (POCT): POCT is gaining traction due to its ability to provide rapid results, which is critical in emergency settings. The point-of-care testing segment is projected to expand at a solid CAGR during the forecasted years.

Industry Latest News

• BridgeBio's Attruby Surpasses Expectations: BridgeBio's heart drug, Attruby, which treats transthyretin amyloid cardiomyopathy, significantly outperformed expectations in its first full quarter on the market, generating $36.7 million in U.S. sales. This positions BridgeBio as a formidable competitor in the expanding cardiomyopathy treatment market.

• Abbott's FDA Approval for Elevate™ Assay: Abbott received FDA approval for its Elevate™ assay, a new generation high-sensitivity troponin test offering improved accuracy for early detection of heart attacks. 

• Quidel's Development of Sofia® BNP Test: Quidel Corporation developed the Sofia® BNP test, a rapid point-of-care test for measuring B-type natriuretic peptide, a key biomarker for heart failure diagnosis and management. 

Key Companies

• Abbott Laboratories: A leading player in the cardiac biomarkers market, offering a range of diagnostic solutions.

• Quidel Corporation: Provides innovative diagnostic products, including cardiac biomarker assays.

• BioMérieux: Specializes in in vitro diagnostics, offering a variety of cardiac biomarker tests.

• Bio-Rad Laboratories: Offers a broad range of life science research and clinical diagnostics products.

• Danaher Corporation: Develops and provides comprehensive diagnostic solutions, including advanced technologies in molecular and immunoassay diagnostics.

• Roche Diagnostics: A global healthcare company providing diagnostic and therapeutic solutions, including cardiac biomarkers.

• Siemens Healthineers: Provides a comprehensive portfolio of diagnostic imaging and laboratory diagnostics.

• Thermo Fisher Scientific: Offers a wide range of diagnostic solutions, including cardiac biomarkers.

• PerkinElmer: Develops, manufactures, and markets tests for the diagnosis of various conditions, including cardiac markers.

Browse In-depth Market Research Report - https://www.marketresearchfuture.com/reports/us-cardiac-biomarkers-market-12821

Market Drivers

• Increasing Prevalence of Cardiovascular Diseases: The growing incidence of CVDs, driven by factors such as aging populations, sedentary lifestyles, and unhealthy diets, is a primary driver of the cardiac biomarkers market.

• Technological Advancements in Diagnostics: Advancements in diagnostic technologies, including the development of high-sensitivity assays and point-of-care testing, are enhancing the accuracy and speed of cardiac biomarker tests.

• Healthcare Awareness and Accessibility: Increased awareness of heart health and the importance of early diagnosis is driving demand for cardiac biomarker tests. Additionally, the development of user-friendly testing methods has improved accessibility.

• Integration of Artificial Intelligence and Big Data: The use of AI and big data analytics in interpreting cardiac biomarker results is improving diagnostic accuracy and enabling personalized treatment strategies.

Regional Insights

The U.S. dominates the North American cardiac biomarkers market, accounting for the largest revenue share due to its advanced healthcare infrastructure and high adoption of diagnostic technologies. In 2024, the U.S. cardiac biomarkers market generated a revenue of USD 8.6 billion and is expected to grow at a CAGR of 14.7% from 2025 to 2030. 

The high prevalence of cardiovascular diseases in the U.S., coupled with the presence of key market players and ongoing research and development activities, contributes to the market's growth. The integration of advanced diagnostic tools and the emphasis on early detection and personalized medicine further bolster the market.